128 related articles for article (PubMed ID: 7526005)
1. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue.
Bushman EC; Nayak RN; Bushman W
J Urol; 1995 Jan; 153(1):233-7. PubMed ID: 7526005
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland.
Agnantis NJ; Constantinidou AE; Papaevagelou M; Apostolikas N
Anticancer Res; 1994; 14(5B):2135-40. PubMed ID: 7530930
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
4. Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia.
Maygarden SJ; Strom S; Ware JL
Arch Pathol Lab Med; 1992 Mar; 116(3):269-73. PubMed ID: 1371380
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
[TBL] [Abstract][Full Text] [Related]
6. Expression of ras oncogene p21 in prostate cancer.
Viola MV; Fromowitz F; Oravez S; Deb S; Finkel G; Lundy J; Hand P; Thor A; Schlom J
N Engl J Med; 1986 Jan; 314(3):133-7. PubMed ID: 2417118
[TBL] [Abstract][Full Text] [Related]
7. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma.
Mohler JL; Chen Y; Hamil K; Hall SH; Cidlowski JA; Wilson EM; French FS; Sar M
Clin Cancer Res; 1996 May; 2(5):889-95. PubMed ID: 9816246
[TBL] [Abstract][Full Text] [Related]
8. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue.
Varma VA; Austin GE; O'Connell AC
Arch Pathol Lab Med; 1989 Jan; 113(1):16-9. PubMed ID: 2462857
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
13. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.
Guo Y; Sklar GN; Borkowski A; Kyprianou N
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2269-74. PubMed ID: 9815624
[TBL] [Abstract][Full Text] [Related]
14. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
15. Lack of the latent transforming growth factor beta binding protein in malignant, but not benign prostatic tissue.
Eklöv S; Funa K; Nordgren H; Olofsson A; Kanzaki T; Miyazono K; Nilsson S
Cancer Res; 1993 Jul; 53(13):3193-7. PubMed ID: 7686449
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of ras oncogene product in neoplastic and non-neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras.
Ramael M; Deblier I; Eerdekens C; Lemmens G; Jacobs W; Van Marck E
J Pathol; 1993 Apr; 169(4):421-4. PubMed ID: 8501538
[TBL] [Abstract][Full Text] [Related]
17. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical study of the prostatic tissues with monoclonal antibody against gamma-seminoprotein. Analyses of benign prostatic hyperplasia, metastatic foci from adenocarcinoma of the prostate and malignant neoplasms other than adenocarcinoma of the prostate].
Fujino A; Shimura S; Murayama M; Ao T; Yokoyama E; Mashimo S; Ishibashi A; Koshiba K; Kuwao S
Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):527-34. PubMed ID: 7685842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
